BioMarin_JPM-2026_FINAL_Jan-12.pdf

《BioMarin_JPM-2026_FINAL_Jan-12.pdf》由会员分享，可在线阅读，更多相关《BioMarin_JPM-2026_FINAL_Jan-12.pdf（26页珍藏版）》请在三个皮匠报告上搜索。

1、BioMarin Pharmaceutical Inc.January 12,202644th AnnualJ.P.Morgan Healthcare ConferenceAlexander HardyChief Executive OfficerGreg FribergChief R&D Officer2Forward-Looking StatementsThis presentation and the associated conference call and webcast contain forward-looking statements about the business p

2、rospects of BioMarin Pharmaceutical Inc.(BioMarin or the company),including,without limitation,statements about:preliminary estimated unaudited financial information for the year ended December 31,2025,including total revenues and revenues from sales of VOXZOGO,as well as the expected asset write-do

3、wn related to ROCTAVIAN and the related impact to BioMarins non-GAAP financial results;expectations related to the consummation of BioMarins proposed acquisition of Amicus Therapeutics and the anticipated benefits of such proposed acquisition,including strategic fit,acceleration of growth and divers

4、ification of revenue,and expectations of substantial accretion beginning in 2027;BioMarins future financial performance,including the expectations of Total Revenues,revenue growth rates,and Non-GAAP Diluted EPS for,in certain instances,the full-year 2026 and future periods,and the underlying drivers

5、 of those results,such as the revenue opportunity represented by treatments for Skeletal Conditions,namely VOXZOGO and BMN 333,the expected demand and continued growth of BioMarins Enzyme Therapies portfolio,including PALYNZIQ and the potential addition of adolescent age label expansion,as well as t

6、he planned expansion of and revenue opportunity represented by Galafold and the planned expansion,accelerated global launch and revenue opportunity of Pombiliti and Opfolda;plans and expectations regarding the development,commercialization and commercial prospects of BioMarins product candidates and